ImmunityBio (IBRX) Reports Q2 Loss, Lags Revenue Estimates
IBRXImmunityBio(IBRX) ZACKS·2024-08-12 22:15

ImmunityBio (IBRX) came out with a quarterly loss of 0.20pershareversustheZacksConsensusEstimateofalossof0.20 per share versus the Zacks Consensus Estimate of a loss of 0.17. This compares to loss of 0.28pershareayearago.Thesefiguresareadjustedfornon−recurringitems.Thisquarterlyreportrepresentsanearningssurpriseof−17.650.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -17.65%. A quarter ago, it was expected that this immunotherapy company would post a loss of 0.16 per share when it actually produced a loss of $0.20, delivering a surprise of -25%.Over the last four quarters, the company has ...